Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL

Journal of Bone Oncology

Volumn 2, Issue 3, 2013, Pages 95-104

  Picarda, Gaelle ^a,b   Matous, Etienne ^a,b   Amiaud, Jerome ^a,b   Charrier, Celine ^a,b   Lamoureux, Francois ^a,b   Heymann, Marie Françoise ^a,b,c   Tirode, Franck ^a   Pitard, Bruno ^d   Trichet, Valerie ^a,b   Heymann, Dominique ^a,b   Redini, Françoise ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c HÔTEL DIEU   (France)

^d L INSTITUT DU THORAX   (France)

Author keywords

Bone resorption; Ewing's sarcoma; Osteoprotegerin; RANKL; TRAIL

Indexed keywords

COPOLYMER; DNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE LESION; BONE REMODELING; BONE STRUCTURE; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENESIS; CONTROLLED STUDY; EWING SARCOMA; EXPERIMENTAL SARCOMA; HOST CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84892817485     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2013.04.004     Document Type: Article

References (50)

1. Ewing J. Classics in Oncology. Diffuse Endothelioma of Bone. In: James Ewing (Ed.), Proceedings of the New York Pathological Society, 1921: CA; Cancer Journal for Clinicians 1972. 22: p. 95-8.
2. Hense HW, Ahrens S, Paulussen M, Lehnert M, Jürgens H. Descriptive epidemiology of Ewing's tumor-analysis of German patients from (EI)CESS 1980-1997. Klinische Padiatrie 1999;211:271-5. (Pubitemid 29364767)
3. Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978-1997. Report from the Automated Childhood Cancer Information System project. European Journal of Cancer 2006;42: 2124-35.
4. Jaffe R, Santamaria M, Yunis EJ, et al. The neuroectodermal tumor of bone. American Journal of Surgical Pathology 1984;8:885-98. (Pubitemid 15161464)
5. Folpe AL, Chand EM, Goldblum JR, Weiss SW. Expression of Fli-1, a nuclear transcription factor, distinguishes vascular neoplasms from potential mimics. American Journal of Surgical Pathology 2001;25:1061-6. (Pubitemid 32685904)
6. May WA, Gishizky ML Lessnick SL, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proceedings of the National Academy of Sciences USA 1993;90:5752-6. (Pubitemid 23176240)
7. Nakatani F, Tanaka K, Sakimura R, et al. Identification of p21WAF1/CIP1 as a direct target of EWS-Eli1 oncogenic fusion protein. Journal of Biological Chemistry 2003;278:15105-15. (Pubitemid 36799844)
8. Dauphinot L, De Oliveira C, Melot T, et al. Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression. Oncogene 2001;20:3258-65. (Pubitemid 32553678)
9. Balamuth NJ, Womer RB. Ewing's sarcoma. Lancet Oncology 2010;11:184-92.
10. Taylor R, Knowles HJ, Athanasou NA. Ewing sarcoma cells express RANKL and support osteoclastogenesis. Journal of Pathology 2011;225:195-202.
11. Chirgwin JM, Guise TA. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Critical Reviews in Eukaryotic Gene Expression 2000;10: 159-78.
12. Simonet WS, Lacey DL Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-19. (Pubitemid 27199902)
13. Wittrant Y, Théoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochimica et Biophysica Acta 2004;1704:49-57. (Pubitemid 39195349)
14. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76. (Pubitemid 28180851)
15. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Rédini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine and Growth Factor Reviews 2004;15:457-75. (Pubitemid 39550455)
16. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochemical and Biophysical Research Communications 1998;247:610-5. (Pubitemid 28418439)
17. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes and Development 1998;12:1260-8. (Pubitemid 28213402)
18. Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 2001;92:460-70. (Pubitemid 32735180)
19. Grimaud E, Soubigou L, Couillaud S, et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. American Journal of Pathology 2003;163:2021-31. (Pubitemid 37310032)
20. Croucher PI, Shipman CM, Lippitt J, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98: 3534-40.
21. Morony S, Capparelli C, Sarosi I, Lacey DL Dunstan CR Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Research 2001;61:4432-6. (Pubitemid 32685771)
22. Lamoureux F, Richard P, Wittrant Y, et al. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Research 2007;67:7308-18. (Pubitemid 47206560)
23. Rousseau J, Escriou V, Perrot P, et al. Advantages of bioluminescence imaging to follow siRNA or chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Therapy 2010;17:387-97.
24. Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Journal of Biological Chemistry 1998;273:14363-7. (Pubitemid 28319153)
25. Holen I, Croucher PI, Hamdy FC, Eaton CL Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Research 2002;62:1619-23. (Pubitemid 34408480)
26. Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Research 2003;63:912-6. (Pubitemid 36278418)
27. Pitard B, Pollard H, Agbulut O, et al. A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles. Human Gene Therapy 2002;13:1767-75. (Pubitemid 35191750)
28. Pitard B, Bello-Roufai M, Lambert O, et al. Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. Nucleic Acids Research 2004;32:e159.
29. Desigaux L, Gourden C, Bello-Roufai M, et al. Nonionic amphiphilic block copolymers promote gene transfer to the lung. Human Gene Therapy 2005;16: 821-9. (Pubitemid 40982331)
30. Richard P, Bossard F, Desigaux L, Lanctin C, Bello-Roufai M, Pitard B. Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles. Human Gene Therapy 2005;16:1318-24. (Pubitemid 41611659)
31. Lamoureux F, Picarda G, Garrigue-Antar L, Baud'huin M, Trichet V, Vidal A, et al. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Research 2009;69:526-36.
32. Rogers MJ, Gordon S, Benford HL Coxon FP, Luckman SP, Monkkonen J, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-78. (Pubitemid 30413179)
33. Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 2005;37:74-86. (Pubitemid 40848420)
34. Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, et al. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Research 2010;70:7610-9.
35. Battaglia S, Dumoucel S, Chesneau J, Heymann MF, Picarda G, Gouin F, et al. Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient. Journal of Bone and Mineral Research 2011;26:2439-51.
36. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. Journal of Molecular Medicine 2001;79:243-53. (Pubitemid 32646379)
37. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999;140:4451-8. (Pubitemid 30666108)
38. Kitazawa S, Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. Journal of Pathology 2002;198:228-36. (Pubitemid 35243881)
39. Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochimica et Biophysica Acta 2004;1704:49-57. (Pubitemid 39195349)
40. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL Nature 2006;440:692-6.
41. Clohisy DR, Ramnaraine ML, Scully S, Qi M, Van HL Lacey DL. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteo-petrotic mice. Journal of Orthopaedic Research 2000;18:967-76. (Pubitemid 32055768)
42. Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Research 2001;61:4038-47. (Pubitemid 32720968)
43. Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant Osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Research 2003;63:287-9. (Pubitemid 36152481)
44. Yonou H, Kanomata N, Goya M, et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Research 2003;63:2096-102. (Pubitemid 36538612)
45. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. Journal of Biological Chemistry 1998;273:14363-7. (Pubitemid 28319153)
46. Lamoureux F, Moriceau G, Picarda G, Rousseau J, Trichet V, Rédini F. Regulation of osteoprotegerin pro- or anti-tumoral activity by bone tumor microenvironment. Biochimica et Biophysica Acta 2010;1805:17-24.
47. Bekker PJ, Hollo way DL Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. Journal of Bone and Mineral Research 2004;19:1059-66. (Pubitemid 41110556)
48. Kostenuik PJ, Nguyen HQ, McCabe J, Warmington KS, Kurahara C. Sun Net al. Denosumab, a fully human monoclonal antibody to RANKL inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. Journal of Bone and Mineral Research 2009;24: 182-95.
49. Terpos E, Efstathiou E, Christoulas D, Roussou M, Katodritou E, Dimopoulos MA. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opinion on Biological Therapy 2009;9:465-79.
50. Lau YS, Adamopoulos IE, Sabokbar A, Giele H, Gibbons CL, Athanasou NA. Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma. British Journal of Cancer 2007;96:1716-22. (Pubitemid 46847198)